Treace Medical Concepts, Inc (TMCI) FinancialsTMCITreace Medical Concepts, Inc

Evaluating the bottom line, Treace Medical Concepts, Inc. maintains a gross margin of 78.47%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -32.96%, while the net margin is -34.98%. These profitability ratios, combined with a Return on Equity (ROE) of -71.99%, provide a clear picture of how effectively TMCI converts its operational activities into shareholder value.

In the context of the broader market, TMCI competes directly with industry leaders such as MYGN and TLSI. With a market capitalization of $311.52M, it holds a leading position in the sector. When comparing efficiency, TMCI's gross margin of 78.47% stands against MYGN's 66.60% and TLSI's 86.78%. Such benchmarking helps identify whether Treace Medical Concepts, Inc. is trading at a premium or discount relative to its financial performance.

The company has shown fluctuating revenue with a total revenue of $45,198,000 for Q1 2026, but continues to operate at a loss with a net income of -$17,961,000 for the same quarter. The gross margin remains strong at around 79%, which is a positive indicator for long-term profitability.